Sustainability momentum STAXS has just launched its 2023 Sustainability Report, signaling a commitment to sustainable practices in contamination control. This presents an opportunity to align with customers prioritizing ESG factors and to propose compliant, eco-conscious containment solutions.

Regulatory quality focus The company operates under ISO 9001:2015 and ISO 13485:2016, indicating strong quality management and medical device manufacturing standards. Sales conversations can emphasize reliability, traceability, and regulatory alignment for pharma and biotech clients.

Regional footprint With established presence in Belgium and the Netherlands and a Dutch headquarters, there is potential to expand into nearby European markets through partnerships, distributors, or direct sales to pharma manufacturers seeking contamination control expertise.

Contamination control expertise Over 30 years of experience in controlled environments positions STAXS as a specialized partner for complete contamination control. This can be marketed to manufacturers seeking turnkey solutions, reducing vendor fragmentation and ensuring consistent quality.

Mid-market focus Revenue in the 1–10M range and a mid-sized employee base signals fit for targeted outreach to regional pharma manufacturers and contract manufacturers looking for scalable, high-touch containment solutions without enterprise-level procurement complexity.